A first research development progress report of the Chromosome 19 Consortium 
with members from Sweden, Norway, Spain, United States, China and India, a part 
of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is 
presented ( http://www.c-hpp.org ). From the chromosome 19 peptide-targeted 
library constituting 6159 peptides, a pilot study was conducted using a subset 
with 125 isotope-labeled peptides. We applied an annotation strategy with triple 
quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the 
quality of data within and in between these instrumental set-ups. LC-MS 
conditions were outlined by multiplex assay developments, followed by MRM assay 
developments. SRM was applied to biobank samples, quantifying kallikrein 3 
(prostate specific antigen) in plasma from prostate cancer patients. The 
antibody production has been initiated for more than 1200 genes from the entire 
chromosome 19, and the progress developments are presented. We developed a 
dedicated transcript microarray to serve as the mRNA identifier by screening 
cancer cell lines. NAPPA protein arrays were built to align with the transcript 
data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first 
development delivery. We have introduced an IT-infrastructure utilizing a LIMS 
system that serves as the key interface for the research teams to share and 
explore data generated within the project. The cross-site data repository will 
form the basis for sample processing, including biological samples as well as 
patient samples from national Biobanks.